251 related articles for article (PubMed ID: 37414719)
1. Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.
González-López TJ; Provan D; Bárez A; Bernardo-Gutiérrez A; Bernat S; Martínez-Carballeira D; Jarque-Ramos I; Soto I; Jiménez-Bárcenas R; Fernández-Fuertes F
Blood Rev; 2023 Sep; 61():101112. PubMed ID: 37414719
[TBL] [Abstract][Full Text] [Related]
2. Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
Garabet L; Ghanima W; Hellum M; Sandset PM; Bussel JB; Tran H; Henriksson CE
Platelets; 2020; 31(3):322-328. PubMed ID: 31280643
[TBL] [Abstract][Full Text] [Related]
3. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
Vianelli N; Auteri G; Buccisano F; Carrai V; Baldacci E; Clissa C; Bartoletti D; Giuffrida G; Magro D; Rivolti E; Esposito D; Podda GM; Palandri F
Ann Hematol; 2022 May; 101(5):963-978. PubMed ID: 35201417
[TBL] [Abstract][Full Text] [Related]
4. Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study.
Åkesson A; Bussel JB; Martin M; Blom AM; Klintman J; Ghanima W; Zetterberg E; Garabet L
Platelets; 2023 Dec; 34(1):2159019. PubMed ID: 36636835
[TBL] [Abstract][Full Text] [Related]
5. Current approaches for the diagnosis and management of immune thrombocytopenia.
Gafter-Gvili A
Eur J Intern Med; 2023 Feb; 108():18-24. PubMed ID: 36424271
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
Kolonić SO; Patekar MB; Milunović V
Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study.
Lee JY; Lee JH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
Thromb Res; 2022 May; 213():114-118. PubMed ID: 35334441
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.
Yang F; Zong H; Li F; Luo S; Zhang X; Xu Y; Zhang X
Platelets; 2023 Dec; 34(1):2135694. PubMed ID: 36281771
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
Podstawka J; Wall E; Bolster L; Patterson JM; Goodyear MD; Rydz N; Sun HL
Thromb Res; 2022 Dec; 220():5-11. PubMed ID: 36257098
[TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials.
Ayad N; Grace RF; Al-Samkari H
Pediatr Blood Cancer; 2022 Mar; 69(3):e29447. PubMed ID: 34962697
[TBL] [Abstract][Full Text] [Related]
12. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.
Červinek L; Mayer J; Doubek M
Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis and Therapy of Immune thrombocytopenia].
Matzdorff A; Wörmann B
Dtsch Med Wochenschr; 2018 Aug; 143(15):1076-1081. PubMed ID: 30060276
[TBL] [Abstract][Full Text] [Related]
14. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
Pulanić D; Bátorová A; Bodó I; Červinek L; Ionita I; Lissitchkov T; Melikyan A; Podolak-Dawidziak M
Ann Hematol; 2023 Apr; 102(4):715-727. PubMed ID: 36826482
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics.
Liebman HA; Pullarkat V
Hematology Am Soc Hematol Educ Program; 2011; 2011():384-90. PubMed ID: 22160062
[TBL] [Abstract][Full Text] [Related]
16. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
Kapur R; Aslam R; Speck ER; Rebetz JM; Semple JW
Platelets; 2020; 31(3):399-402. PubMed ID: 31146647
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
Gudbrandsdottir S; Frederiksen H; Hasselbalch H
Platelets; 2012; 23(6):423-9. PubMed ID: 22185370
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
Makar RS; Zhukov OS; Sahud MA; Kuter DJ
Am J Hematol; 2013 Dec; 88(12):1041-4. PubMed ID: 23913253
[TBL] [Abstract][Full Text] [Related]
20. Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options.
Mititelu A; Onisâi MC; Roșca A; Vlădăreanu AM
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]